250 related articles for article (PubMed ID: 31594977)
1. Hemophilia A and B mice, but not VWF
Taves S; Sun J; Livingston EW; Chen X; Amiaud J; Brion R; Hannah WB; Bateman TA; Heymann D; Monahan PE
Sci Rep; 2019 Oct; 9(1):14428. PubMed ID: 31594977
[TBL] [Abstract][Full Text] [Related]
2. Increased bone resorption in hemophilia.
Rodriguez-Merchan EC; Valentino LA
Blood Rev; 2019 Jan; 33():6-10. PubMed ID: 29857920
[TBL] [Abstract][Full Text] [Related]
3. Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival.
Baud'huin M; Duplomb L; Téletchéa S; Charrier C; Maillasson M; Fouassier M; Heymann D
J Biol Chem; 2009 Nov; 284(46):31704-13. PubMed ID: 19758994
[TBL] [Abstract][Full Text] [Related]
4. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
Shi Q; Schroeder JA; Kuether EL; Montgomery RR
J Thromb Haemost; 2015 Jul; 13(7):1301-9. PubMed ID: 25955153
[TBL] [Abstract][Full Text] [Related]
5. Similarity in joint and mucous bleeding syndromes in type 2N von Willebrand disease and severe hemophilia A coexisting with type 1 von Willebrand disease in two Chinese pedigrees.
Qin HH; Xing ZF; Wang XF; Ding QL; Xi XD; Wang HL
Blood Cells Mol Dis; 2014 Apr; 52(4):181-5. PubMed ID: 24351655
[TBL] [Abstract][Full Text] [Related]
6. The bone disease associated with factor VIII deficiency in mice is secondary to increased bone resorption.
Recht M; Liel MS; Turner RT; Klein RF; Taylor JA
Haemophilia; 2013 Nov; 19(6):908-12. PubMed ID: 23731369
[TBL] [Abstract][Full Text] [Related]
7. Gene Therapy for Hemophilia.
Nienhuis AW; Nathwani AC; Davidoff AM
Mol Ther; 2017 May; 25(5):1163-1167. PubMed ID: 28411016
[TBL] [Abstract][Full Text] [Related]
8. Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice.
Milanov P; Ivanciu L; Abriss D; Quade-Lyssy P; Miesbach W; Alesci S; Tonn T; Grez M; Seifried E; Schüttrumpf J
Blood; 2012 Jan; 119(2):602-11. PubMed ID: 22031860
[TBL] [Abstract][Full Text] [Related]
9. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.
Seth Chhabra E; Liu T; Kulman J; Patarroyo-White S; Yang B; Lu Q; Drager D; Moore N; Liu J; Holthaus AM; Sommer JM; Ismail A; Rabinovich D; Liu Z; van der Flier A; Goodman A; Furcht C; Tie M; Carlage T; Mauldin R; Dobrowsky TM; Liu Z; Mercury O; Zhu L; Mei B; Schellenberger V; Jiang H; Pierce GF; Salas J; Peters R
Blood; 2020 Apr; 135(17):1484-1496. PubMed ID: 32078672
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
Miller CH; Kelley L; Green D
Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
[TBL] [Abstract][Full Text] [Related]
11. Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.
Swystun LL; Ogiwara K; Rawley O; Brown C; Georgescu I; Hopman W; Labarque V; Male C; Thom K; Blanchette VS; Carcao MD; Lillicrap D
Blood; 2019 Sep; 134(11):880-891. PubMed ID: 31350267
[TBL] [Abstract][Full Text] [Related]
12. Application of a molecular diagnostic algorithm for haemophilia A and B using next-generation sequencing of entire F8, F9 and VWF genes.
Bastida JM; González-Porras JR; Jiménez C; Benito R; Ordoñez GR; Álvarez-Román MT; Fontecha ME; Janusz K; Castillo D; Fisac RM; García-Frade LJ; Aguilar C; Martínez MP; Bermejo N; Herrero S; Balanzategui A; Martin-Antorán JM; Ramos R; Cebeiro MJ; Pardal E; Aguilera C; Pérez-Gutierrez B; Prieto M; Riesco S; Mendoza MC; Benito A; Hortal Benito-Sendin A; Jiménez-Yuste V; Hernández-Rivas JM; García-Sanz R; González-Díaz M; Sarasquete ME
Thromb Haemost; 2017 Jan; 117(1):66-74. PubMed ID: 27734074
[TBL] [Abstract][Full Text] [Related]
13. Hemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche T; Chuah MK
Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis and treatment of osteoporosis in patients with hemophilia.
Lin X; Gao P; Zhang Q; Jiang Y; Wang O; Xia W; Li M
Arch Osteoporos; 2023 Jan; 18(1):17. PubMed ID: 36598583
[TBL] [Abstract][Full Text] [Related]
15. Platelet and endothelial expression of clotting factors for the treatment of hemophilia.
Montgomery RR; Shi Q
Thromb Res; 2012 May; 129 Suppl 2(Suppl 2):S46-8. PubMed ID: 22421106
[TBL] [Abstract][Full Text] [Related]
16. Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis.
Sun J; Hua B; Livingston EW; Taves S; Johansen PB; Hoffman M; Ezban M; Monroe DM; Bateman TA; Monahan PE
Blood; 2017 Apr; 129(15):2161-2171. PubMed ID: 28039188
[TBL] [Abstract][Full Text] [Related]
17. Gene Therapy in Hemophilia: Recent Advances.
Rodríguez-Merchán EC; De Pablo-Moreno JA; Liras A
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299267
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of vascular permeability and remodeling associated with hemarthrosis in factor VIII-deficient mice.
Cooke EJ; Wyseure T; Zhou JY; Gopal S; Nasamran CA; Fisch KM; Manon-Jensen T; Karsdal MA; Mosnier LO; von Drygalski A
J Thromb Haemost; 2019 Nov; 17(11):1815-1826. PubMed ID: 31301687
[TBL] [Abstract][Full Text] [Related]
19. Defining severity of hemophilia: more than factor levels.
Pavlova A; Oldenburg J
Semin Thromb Hemost; 2013 Oct; 39(7):702-10. PubMed ID: 24026911
[TBL] [Abstract][Full Text] [Related]
20. Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice.
Pisal DS; Kosloski MP; Middaugh CR; Bankert RB; Balu-Iyer SV
J Pharm Sci; 2012 Jun; 101(6):2055-65. PubMed ID: 22388918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
